Oncogard

What Oncogard does

Oncogard is a private medical oncology practice (cabinet libéral) headquartered at the Institut de Cancérologie du Gard in Nîmes, France, with a secondary site at Centre Hospitalier Alès Cévennes in Alès. The practice has been operating in the Gard department since the 1980s and treats patients with malignant tumor pathologies across eight cancer types (breast, prostate, lung, bladder, gynecological, digestive, brain, and head/neck) through five core modalities: radiotherapy, chemotherapy, immunotherapy, hormonotherapy, and targeted therapy. The center is led by Dr. Éric Legouffe (President, oncologist, joined 2006) with Pauline Baudière as Director of Operations since May 2023, supported by a 15-person multidisciplinary team.

The practice has invested in clinical technology differentiation, deploying Vision RT surface-guided radiotherapy in April 2025 (making it one of the first centers in Gard to offer this precision system) and an ECG tele-expertise platform developed with Elsan, Novartis, and Bannook Group that enables cardiac monitoring during oncology consultations. Supportive care services — psychology, socio-aesthetics, art therapy, hypno-therapy, meditation, and patient education workshops — are delivered through the Espace de Rencontres et d'Information (ERI) and partnerships with associations such as Ligue contre le Cancer du Gard, Réseau DIANE, Les Roses du Gard, and onCOGITE. The center also maintains strategic ties to the Elsan group's regional facilities (Clinique Bonnefon, Polyclinique Kenval, Polyclinique Grand Sud, Hôpital Privé Les Franciscaines).

Revenue is generated entirely through direct patient care reimbursed by the French Sécurité sociale under the ALD (Affection Longue Durée) framework at 100% of tariff-based pricing with no fee overruns. Patients access services via physician referrals or self-referral for initial consultations, after which multidisciplinary treatment plans are developed. Distribution is regional, limited to the Occitanie region (Gard department), with all activity concentrated across the two physical sites. Marketing is primarily content-driven (educational blog, awareness campaigns such as Mars Bleu and Octobre Rose) and community-based (workshops, association events). The ownership structure is physician-led with no identified parent company, institutional investor, or external capital.

Name

Oncogard

Legal name

Oncogard

Website

https://oncogard.fr

Company type

Private

Founded year

1980

Operating status

Operating

Headcount range

11–50 employees

Short description

Oncogard is a private medical oncology center operating since the 1980s across two sites in Nîmes and Alès, France, providing radiotherapy, chemotherapy, immunotherapy, hormonotherapy, and targeted therapy to cancer patients under the French ALD reimbursement framework, with integrated supportive care and association-based community programs.

Ownership category

akta.pro rank

Product category

Oncology Medical Services

NAICS

Ambulatory Health Care Services (621), Other Outpatient Care Centers (62149)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI)

akta.pro secondary industries

Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM), Medical Oncology (HLAKAFAB)

Keywords

• Oncology medical services
• Cancer treatment center
• Radiotherapy services
• Chemotherapy treatment
• Supportive cancer care

Headquarters

HQ city

Nîmes

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Oncology Medical Services: Medical consultations and oncology treatments (chemotherapy, radiotherapy, immunotherapy, hormonotherapy, targeted therapy) covered by French social security through the ALD (Affections Longue Durée) system. Treatments are reimbursed at 100% by Sécurité sociale for eligible cancer patients.
2. Supportive Care Services: Supportive care services including psychology, socio-aesthetics, art therapy, hypno-therapy, meditation, and patient education workshops, often provided through partnerships with associations or partially covered by health insurance.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Oncogard is a private medical oncology center (cabinet libéral) operating at two sites in Nîmes and Alès, France, since the 1980s. It provides comprehensive cancer treatment through five core modalities: radiotherapy, chemotherapy, immunotherapy, hormonotherapy, and targeted therapy, along with supportive care services including psychology, art therapy, hypno-therapy, and patient education workshops. The center treats malignant tumors across breast, prostate, lung, bladder, gynecological, digestive, brain, and head/neck cancer types.

Product overview

Oncogard is a liberal medical oncology center present on two sites in Nîmes and Alès since the 1980s. The center provides comprehensive cancer treatment through five core treatment modalities: radiotherapy (with Vision RT technology), chemotherapy, immunotherapy, hormonotherapy, and targeted therapy. These treatments address malignant tumor pathologies across eight cancer types: breast, prostate, lung, bladder, gynecological, digestive, brain, and head/neck cancers. The center integrates supportive care services including the ERI (Espace de Rencontres et d'Information), supportive care programs, cardiac tele-expertise, and patient support workshops. The facility operates within the Institut de Cancérologie du Gard (ICG) in Nîmes and partners with Centre Hospitalier Alès Cévennes for the Alès location.

Differentiator

Problem solved

Functional benefit

Products and services

• Radiotherapy Treatment (Radiothérapie) External beam radiotherapy using radiation to destroy cancer cells, enhanced with Vision RT surface-guided technology for precise patient positioning and automatic beam interruption on movement detection.
• Chemotherapy Treatment (Chimiothérapie)
• Immunotherapy Treatment (Immunothérapie)
• Hormonotherapy Treatment (Hormonothérapie)
• Targeted Therapy (Thérapie Ciblée)
• Cardiac Tele-expertise (Téléexpertise cardiaque) ECG solution developed in partnership with Elsan, Novartis, and Bannook Group, enabling electrocardiogram realization during oncology consultations with remote cardiologist interpretation.
• Supportive Care (Soins de Support)
• Espace de Rencontres et d'Information (ERI)

Quantifiable outcome

• Vision RT enables automatic beam interruption for patient safety during radiotherapy
• +1 more outcomes

Named customers2 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• onCOGITEcoreStrategic or Co-development Partner · 8 June 2023Official partnership announced June 8, 2023 for collaborative patient support and awareness activities.
• Clinique BonnefoncoreStrategic or Co-development PartnerHealthcare facility partnership for coordinated cancer care delivery. Located within or connected to the Elsan healthcare group network.
• Polyclinique KenvalcoreStrategic or Co-development PartnerElsan group healthcare facility partnership for integrated oncology services in the Nîmes region.
• Polyclinique Grand SudcoreStrategic or Co-development PartnerElsan group healthcare facility partnership providing comprehensive cancer care coordination.
• Hôpital Privé Les FranciscainescoreStrategic or Co-development PartnerElsan group hospital partnership for integrated oncology care delivery.
• Centre Hospitalier Alès CévennescoreStrategic or Co-development PartnerHost facility for Oncogard's Alès location, providing inpatient and emergency services for coordinated patient care.
• Réseau DIANEcoreStrategic or Co-development PartnerNetwork of healthcare professionals providing structured support for breast cancer patients from diagnosis through treatment completion, including psychological, social, and medical support. Created by liberal healthcare professionals in Nîmes.
• ElsancoreStrategic or Co-development PartnerHealthcare group partnership for innovative care solutions including tele-expertise ECG monitoring system for cardiac safety during cancer treatment.
• NovartiscoreStrategic or Co-development PartnerPharmaceutical company partnership for enabling tele-expertise ECG solution to expand therapeutic options for cancer patients, particularly metastatic breast cancer patients on targeted therapy.
• Ligue contre le Cancer du GardcoreStrategic or Co-development PartnerCancer association providing supportive care services including hypno-therapy, psychological support, and social worker assistance for administrative procedures. Regular presence during association Mondays at ICG.
• Les Roses du GardminorStrategic or Co-development PartnerBreast cancer patient association participating in monthly meetings at ICG and awareness events.
• Association DianecoreStrategic or Co-development PartnerBreast cancer patient support network providing care pathway coordination, therapeutic workshops, and patient guidance services.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Institut Curie: Paris/Saint-Cloud cancer centre combining hospital-based multi-modality oncology treatment with research and supportive care; comparable to Oncogard in patient pathway structure, although operating at significantly larger scale.
• Institut du Cancer de Montpellier (ICM): Unicancer CLCC located within ~1 hour of Nîmes providing the same five-modality oncology service mix; the closest direct clinical competitor for patient referrals in Oncogard's broader catchment.
• Institut Paoli-Calmettes: Marseille-based comprehensive cancer centre offering chemotherapy, radiotherapy, immunotherapy, hormonotherapy and targeted therapy with embedded supportive care — direct functional peer to Oncogard in a different regional catchment.
• Centre Léon Bérard: CLCC comprehensive cancer centre in Lyon providing multi-modality oncology care, supportive care and clinical research — directly comparable to Oncogard in scope of services and patient pathway design, though at national scale.
• Institut de Cancérologie de l'Ouest (ICO): Comprehensive cancer centre in Western France delivering the same five core oncology treatment modalities (chemo, radiotherapy, immunotherapy, hormonotherapy, targeted therapy) across multiple sites — a direct private/non-profit analogue to Oncogard's regional multi-site model.
• Centre Jean Perrin: Clermont-Ferrand CLCC delivering the same chemotherapy/radiotherapy/immunotherapy/hormonotherapy/targeted therapy mix and supportive care services; functionally a sister regional cancer centre to Oncogard.

Others

• Unicancer: Federation of France's 18 CLCC cancer centres; not a competitor for Oncogard's specific catchment but the institutional benchmark and counterparty network shaping reimbursement, clinical guidelines, and clinical-trial access that Oncogard benchmarks itself against.

Broad incumbents

• Elsan Group: Major French private hospital group whose clinics (Clinique Bonnefon, Polyclinique Kenval, Polyclinique Grand Sud, Hôpital Privé Les Franciscaines) host and partner with Oncogard — a strategic ecosystem peer and de facto referral backbone.
• Gustave Roussy: Europe's largest comprehensive cancer centre; while much bigger, it sets the reference standard for multi-modality oncology, supportive care and innovation that Oncogard's positioning (Vision RT, tele-expertise) aims to emulate at regional scale.
• Ramsay Santé: France's leading private hospital group operating private oncology units across the country; comparable as a broad private-sector operator competing with Elsan-affiliated providers like Oncogard for ambulatory oncology volumes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=0rUb5XG7zAE
• LinkedInlinkedin.com/company/oncogard

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oncogard